Unavailable
Unavailable
Save time and jump to the most important pieces.
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV
Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m
New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform
Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m
4 - Petra Acquisition Inc. (0001810560) (Issuer)
3 - Petra Acquisition Inc. (0001810560) (Issuer)
4 - Petra Acquisition Inc. (0001810560) (Issuer)
SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)
SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)
SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Revelation Biosciences Inc (NASDAQ:REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines. Each cell line expressed sufficient levels of ACEII and TLR4, receptors required to sufficiently demonstrate viral infection as well as REVTx-99 activity, respectively. Why It Matters: Human primary bronchial/tracheal and alveolar epithelial cells were treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour and 24 hours before infection, respectively. In both the cell lines, vi
Revelation Biosciences Inc (NASDAQ:REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines. Each cell line expressed sufficient levels of ACEII and TLR4, receptors required to sufficiently demonstrate viral infection as well as REVTx-99 activity, respectively. Why It Matters: Human primary bronchial/tracheal and alveolar epithelial cells were treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour and 24 hours before infection, respectively. In both the cell lines, vi
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows And Highs: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to hit a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). Aligos Therapeutics (NASDAQ:ALGS) saw the largest move of the companies, as shares plummetted 46.75% to hit a new 52-week low. Vimeo (NASDAQ:VMEO) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks created new 52-week lows as of 10am on Thursday: Rivian Automotive (NASDAQ:RIVN) stock achieved a new 52-week low on Thursday morning, hitting $75